
Join the Fight Against Lyme Disease!
We are looking for people recently diagnosed with Lyme disease to help us answer important questions about the infection. If you have or had the rash associated with acute Lyme disease (erythema migrans), facial palsy, meningitis, heart block, or arthritis; please consider participating in our study.

Research Study for Severe Aplastic Anemia (SAA)
Doctors at the National Institutes of Health (NIH) are conducting a research study to determine the viability and safety of early initiation of oral therapy with cyclosporine and eltrombopag in patients with severe aplastic anemia (SAA).

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients with Systemic Lupus Erythematosus

Clinical Evaluation of Pediatric and Adults with Myelodysplastic Syndromes (MDS)
Myelodysplastic syndromes (MDS) are disorders caused by abnormal blood cell production, potentially leading to low cell counts and increased susceptibility to clotting and infections. Past research suggests that inflammation may trigger these abnormalities, and this study seeks to further understand and improve treatment strategies for MDS by investigating the role of inflammation in bone marrow cell development.

NIH Tests Fostamatinib for Post-Transplant Cytopenia(s)
After stem cell transplantation, some people develop hard-to-treat anemia (low red blood cells) or thrombocytopenia (low platelets). Cytopenia(s) or low blood cell counts make you weak, prone to bleeding and bruising, and dependent on blood product transfusions. Researchers at the National Institutes of Health (NIH) are testing the drug fostamatinib to see if it is safe to treat cytopenia(s) after stem cell transplantation. A physician referral is not required to participate.

Observational Study of Cardiac Arrhythmias in Subjects Treated with BTK Inhibitors

Studies of the Natural History of Sickle Cell Disease
The research study aims to enhance the understanding of SCD and its associated complications by investigating the relationship between the disease and specific variations of certain genes. If you have SCD, your participation in this study is highly valuable. By participating, you will undergo an evaluation and receive recommendations from a team experienced in the treatment and management of SCD.

Phase II Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss among Individuals with Head and Neck Cancer (En español)
Doctors at the National Institute on Deafness and Other Communication Disorders (NIDCD) are investigating the effectiveness of atorvastatin (a drug used to lower “bad“ cholesterol and fats such as LDL, and triglycerides, and raise “good“ cholesterol such as HDL, in the blood) at reducing the incidence of hearing loss in patients treated with cisplatin for head and neck cancer. (En español)

Phase II Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss among Individuals with Head and Neck Cancer
Doctors at the National Institute on Deafness and Other Communication Disorders (NIDCD) are investigating the effectiveness of atorvastatin (a drug used to lower “bad“ cholesterol and fats such as LDL, and triglycerides, and raise “good“ cholesterol such as HDL, in the blood) at reducing the incidence of hearing loss in patients treated with cisplatin for head and neck cancer.
